Regeneron Deal History & Licensing Activity
Regeneron is a large biotech headquartered in US. Over the past three years, Regeneron has been involved in 26 licensing and acquisition transactions, with a primary focus on Gene Therapy (7 deals). The company currently has 50 active clinical trials, primarily in Oncology.
Deals (12mo)
8
Active Trials
50
Top Modality
Gene Therapy
Focus Area
Oncology
Regeneron Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Regeneron in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| radiopharma program | Telix Pharmaceuticals | Radiopharmaceuticals | Unknown | license | Apr 2026 |
| Radiopharma program | Telix | Radiopharmaceuticals | Unknown | license | Apr 2026 |
| Undisclosed | Regeneron Pharmaceuticals, Inc. | Radiopharmaceuticals | Discovery | collaboration | Apr 2026 |
Regeneron Pipeline Focus
Therapeutic areas and modalities where Regeneron is most active based on deal history and clinical trial data.
Therapeutic Areas
Regeneron Strategic Signals
Key indicators of Regeneron's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Patent Cliffs
- Undisclosed—
- Undisclosed—
Revenue at Risk (LOE)
Patent expirations create urgency for Regeneron to replace revenue through in-licensing or acquisitions.
Strategic Profile
Acquisition Appetite
Regeneron Clinical Pipeline
Regeneron has 50 active clinical trials across 5 development phases.
2
Phase 4
4
Unknown
8
Phase 1
21
Phase 2
15
Phase 3
See How Your Asset Matches Regeneron's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Oncology assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Gene Therapy Benchmarks
Upfront, milestone, and royalty benchmarks for gene therapy deals
Radiopharmaceuticals Benchmarks
Upfront, milestone, and royalty benchmarks for radiopharmaceuticals deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
About Regeneron Licensing & Deal Activity
Regeneron is a large biotech company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 26 deals over the past three years, Regeneron ranks among the most acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Regeneron include Oncology (24 deals and trials), Solid Tumors (14 deals and trials), Hematological Malignancies (8 deals and trials), and Cardiovascular (7 deals and trials). In terms of modality, Regeneron has shown particular interest in gene therapy, radiopharmaceuticals, cell therapy.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Regeneron and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Regeneron's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.